Wed.Sep 25, 2024

article thumbnail

For Pharmacists With Substance Use Disorders, Recovery Is Possible

Drug Topics

Pharmacy professionals are at an increased risk of substance abuse due to many factors, but long-term recovery can be achieved with the help of specialized recovery networks.

154
154
article thumbnail

Can MRIs ensure prostate cancer screening does more good than harm?

STAT

Prostate cancer presents a tricky screening challenge. Catching it early could mean dodging a painful journey with advanced cancer. Yet a sizable majority of prostate cancers are “indolent” — slow growing tumors that most likely would never metastasize during the patient’s lifetime, and whose treatment  would do more harm than good.

144
144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Immunization Roundup: FDA Approves FluMist, Updated Novavax COVID-19 Vaccine

Drug Topics

Catch up on important immunization news from the month of September.

article thumbnail

STAT+: The little-known Chinese biotech whose cancer drug beat Keytruda has global ambitions

STAT

Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less attention has been paid to Akeso, a Chinese biotech that had kept a low profile until its drug bested Merck’s mega-blockbuster Keytruda in a late-stage lung cancer trial.  Now, Akeso’s leaders want you to know that its recent success isn’t a one-off.

144
144
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Although AI Tools Are Advancing, Expert Says There Is a Need for More Tools Post-Diagnosis in Myeloma

Pharmacy Times

Although Madabhushi said there are emerging tools for clinical decision support, he said there is a greater need for tools further downstream in the post-diagnosis stages.

142
142
article thumbnail

STAT+: Can Anne Wojcicki save 23andMe?

STAT

Usually, introductory meetings with startup executives are perfunctory and fade to irrelevance within an hour. But I still remember the first moment I met 23andMe CEO and co-founder Anne Wojcicki in 2007. My editor at the time had set up a meeting between my reporting partner and I and Wojcicki, along with 23andMe co-founder Linda Avey, at an upscale sandwich shop on East 13th Street in New York City.

143
143

More Trending

article thumbnail

STAT+: Pfizer pulls sickle cell treatment Oxbryta off global markets

STAT

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.  The decision is a stunning blow for a drug that was approved in 2019 , heralded as a new way to treat the inherited blood disorder. Pfizer acquired the maker of Oxbryta, a biotech company called Global Blood Therapeutics, in 2022 for $5.4 billion.

142
142
article thumbnail

J.D. Power: Consumer experience with telehealth a mixed bag

Fierce Healthcare

While consumers give telehealth high marks for convenience, overall experience is fairly mixed, according to a new report. | While consumers give telehealth high marks for convenience, overall experience is fairly mixed, according to a new report.

131
131
article thumbnail

Opinion: Veterinary medicine is key to overcoming antimicrobial resistance

STAT

Over the three decades that I have worked in animal health, I have borne witness to the mounting effects of antimicrobial resistance (AMR) in animals. Just like in people, while bacterial infections in animals were once predictably treatable with routine antimicrobials, we now face resistant infections that make it harder to treat animals. Then we end up on a slippery slope of needing to use newer antimicrobials, helping to treat the infection but adding risks for development of even more resist

142
142
article thumbnail

Biosimilars Provide VA With Cost Savings for Treatment of Psoriasis

Pharmacy Times

Additional education can address ambivalence for patients and providers, which can start at the pharmacist level, as they are essential sources of information for patients.

130
130
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Ozempic linked to lower opioid overdose rate in those with diabetes, study shows

STAT

People taking semaglutide medications like Ozempic for diabetes may be at reduced risk of drug overdose, according to new research. Prescriptions for semaglutide, which includes Ozempic and Rybelsus, were linked to lower overdose rates among patients with type 2 diabetes who were also diagnosed with opioid use disorder, according to a paper published Wednesday.

142
142
article thumbnail

MA insurer Zing Health banks $140M to build out its special needs plan

Fierce Healthcare

Startup Medicare Advantage insurer Zing Health banked a $140 million funding round it intends to use to enhance its special needs plans. | Startup Medicare Advantage insurer Zing Health banked a $140 million funding round it intends to use to enhance its special needs plans.

Insurance 130
article thumbnail

STAT+: Celldex drug reduces chronic hive activity, but patient discontinuations raise questions

STAT

Celldex Therapeutics reported Wednesday that its experimental medicine for a condition that causes chronic hives reduced hive activity in patients, completely clearing it in some.  However, there was a high rate of patient discontinuations in the trial, due in part to side effects including changes in hair color. Those concerns sent Celldex shares down more than 20% following the company’s announcement.

135
135
article thumbnail

Provider surveys, vendor benchmarking data underscore rising claims denial rates

Fierce Healthcare

Recent survey and system data are again suggesting that payers’ increasing claims denials are a pain point for healthcare providers. | A new revenue cycle leadership survey from Experian Health, monthly dashboard updates from Kodiak Solutions and other recent commentary paint a picture of more demanding payers.

126
126
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

How Special Olympics kickstarted the push for better disability data

STAT

On July 1st, 1995, the world’s spotlight shone upon Yale’s football stadium in New Haven, Connecticut. It was the latest Special Olympics World Games, and the organizers had lined up big-name musicians like Hootie & the Blowfish and Boyz II Men for the opening ceremony. United States President Bill Clinton and First Lady Hillary Clinton even made an appearance.

135
135
article thumbnail

Pancreatic Cancer Has a Growing Array of Treatment Options

Pharmacy Times

However, early diagnosis still presents challenges and limits treatment options.

125
125
article thumbnail

STAT+: Generic drug lobby taps former BIO exec as new CEO

STAT

WASHINGTON — The trade association for generic drugs and biosimilars has chosen a new leader: John Murphy. Four sources familiar with the decision said Murphy will be named as the new head of the Association for Accessible Medicines. AAM declined to comment on the CEO selection, but a spokesperson for the group said it will make an announcement later Wednesday.

135
135
article thumbnail

Nonprofit hospitals received $37.4B in federal, local tax benefits in 2021, study finds

Fierce Healthcare

The nonprofit hospital sector’s tax exemptions provide billions in estimated benefits, but about half of those exemptions are enjoyed by just a couple hundred hospitals, according to a newly publis | The analysis, meant to serve as a guide for policymakers, noted that the tax breaks are "highly concentrated" and vary "substantially" from state to state.

Hospitals 124
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Leveraging AI for More Accurate Multiple Myeloma Predictions

Pharmacy Times

Artificial intelligence shows promise in improving diagnosis and treatment for patients with multiple myeloma.

123
123
article thumbnail

With success in myasthenia gravis trial, Amgen's Uplizna looks set up to add new indication

Fierce Pharma

Three months after Amgen revealed that Uplizna had aced a phase 3 trial in immunoglobulin G4-related disease (IgG4), the company said the anti-CD-19 antibody has excelled in a study against another | Three months after Amgen revealed that Uplizna had aced a phase 3 trial in IgG4, the company said the anti-CD-19 antibody has excelled in a study against another neurologic disorder, myasthenia gravis.

122
122
article thumbnail

How to advance diversity, equity and inclusion in clinical trial recruitment

pharmaphorum

Discover strategies and best practices for advancing diversity, equity, and inclusion (DEI) in clinical trial recruitment. Learn how to improve representation and access for underrepresented populations.

121
121
article thumbnail

Citing enrollment challenges, Bristol Myers and 2seventy scrap Abecma trial in first-line myeloma

Fierce Pharma

Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma has hit a major setback. Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial in first-line myeloma after struggling to enroll patients.

116
116
article thumbnail

Pfizer pulls sickle cell med Oxbryta off market after deaths

pharmaphorum

Pfizer is voluntarily withdrawing its sickle cell drug Oxbryta after a review revealed an imbalance of deaths in clinical trials

119
119
article thumbnail

IntraBio muscles in on Zevra's turf after companies' back-to-back lysosomal storage disorder nods

Fierce Pharma

While it was just last week that Zevra Therapeutics’ Miplyffa became the first FDA-approved treatment for the lysosomal storage disorder Niemann-Pick disease type C (NPC), IntraBio has already one- | While it was just last week that Zevra Therapeutics’ Miplyffa became the first FDA-approved treatment for the lysosomal storage disorder Niemann-Pick disease type C, IntraBio has already one-upped its rare disease rival.

FDA 115
article thumbnail

Novo Nordisk CEO reticent on lowering semaglutide prices

pharmaphorum

Novo Nordisk chief executive Lars Fruergaard Jørgensen was taken to task by US lawmakers over the price of the company's semaglutide drugs for diabetes and obesity at a congressional hearing yesterday – but would not commit to reducing them. Jørgensen danced around the topic of price cuts, saying Novo Nordisk supported "anything that helps patients get access and affordability […] we will look into.

115
115
article thumbnail

The science behind Summit’s success, 23andMe’s fate, and more biotech news updates

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning. Which CEO drank out of my colleague Matt Herper’s glass of water? Read on today to find out!

113
113
article thumbnail

Antidepressants Found Ineffective for Treating Osteoarthritis Pain in Older Adults

Drug Topics

Researchers conducted a meta-analysis and systematic review to determine the efficacy of using antidepressants to treat older adults for knee osteoarthritis pain.

112
112
article thumbnail

Private equity firms bid on Sanofi's $16B+ consumer health business: Bloomberg

Fierce Pharma

As private equity firms reportedly place their bids, Sanofi may soon follow in the footsteps of GSK and Johnson & Johnson with the separation of its consumer health unit. | Sanofi has received two private equity offers for its consumer health business, which could be valued at 15 billion euros ($16.7 billion) or more, Bloomberg reported Tuesday, citing people close to the matter.

111
111
article thumbnail

Higher Buprenorphine Doses May Reduce Health Care Utilization for OUD

Drug Topics

Higher doses of buprenorphine may also be more effective against the increasing prevalence of fentanyl in the opioid crisis.

112
112
article thumbnail

AI firm Generate signs $1bn discovery deal with Novartis

pharmaphorum

Flagship Pioneering-backed artificial intelligence startup Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis.The wide-ranging deal, worth up to $1 billion, covers multiple targets and disease areas and focuses on the discovery and development of protein-based therapeutics using Generate's generative AI (genAI) platform.

111
111
article thumbnail

FDA Approves Levacetylleucine for Treatment of Niemann-Pick Disease Type C

Drug Topics

The approval comes shortly after the FDA approved arimoclomol from Zevra Therapeutics to treat neurological manifestations of the disease in combination with miglustat.

FDA 112
article thumbnail

Lilly gets second approval, in Japan, for Alzheimer's drug

pharmaphorum

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug

109
109
article thumbnail

Pharmacy closures in England threaten plan to use them instead of GPs for some care

The Guardian - Pharmaceutical Industry

Closure of hundreds of outlets hitting rural areas, older people and deprived communities hardest, according to Healthwatch England High street pharmacies are closing at such an alarming rate that it threatens the drive to use them instead of GPs to care for millions of people, the NHS’s patient champion warns today. A total of 436 community pharmacies in England shut permanently last year and there were also 13,863 temporary closures, which stopped patients from obtaining health advice and medi